Alector provides executive leadership update

-- neil berkley, m.b.a., appointed interim chief financial officer, succeeding marc grasso, m.d.,  effective june 20, 2025 -- south san francisco, calif., june 13, 2025 (globe newswire) -- alector, inc. (nasdaq: alec), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its chief financial officer (cfo), marc grasso, m.d., will conclude his tenure with the company, effective june 20, 2025, to pursue other opportunities. neil berkley, m.b.a., the company's chief business officer, will assume the role of interim cfo while continuing in his current position.
ALEC Ratings Summary
ALEC Quant Ranking